Tandem Diabetes Care Files 8-K with Corporate Updates
Ticker: TNDM · Form: 8-K · Filed: Dec 30, 2025 · CIK: 1438133
| Field | Detail |
|---|---|
| Company | Tandem Diabetes Care Inc (TNDM) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financial-reporting
Related Tickers: TNDM
TL;DR
Tandem Diabetes Care filed an 8-K on 12/30/25 for corporate updates as of 12/26/25.
AI Summary
Tandem Diabetes Care, Inc. filed an 8-K on December 30, 2025, reporting events as of December 26, 2025. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing indicates potential changes in Tandem Diabetes Care's corporate structure or governance, which could impact its operational framework and shareholder rights.
Risk Assessment
Risk Level: low — The filing is routine and pertains to corporate governance and financial reporting, not immediate operational or financial distress.
Key Numbers
- 001-36189 — SEC File Number (Identifies the company's filing with the SEC.)
- 20-4327508 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Tandem Diabetes Care, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- December 26, 2025 (date) — Date of earliest event reported
- December 30, 2025 (date) — Date of Report
FAQ
What specific amendments were made to Tandem Diabetes Care's Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What is the nature of the financial statements and exhibits included in this filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided header information.
When is Tandem Diabetes Care's fiscal year-end?
Tandem Diabetes Care's fiscal year ends on December 31.
What is the principal executive office address for Tandem Diabetes Care?
The principal executive offices are located at 12400 High Bluff Drive, San Diego, California, 92130.
What is the significance of the 'Date as of Change' being December 30, 2025?
This date likely signifies the effective date of the reported changes or the date the information became official for the filing.
Filing Stats: 1,132 words · 5 min read · ~4 pages · Grade level 17.1 · Accepted 2025-12-30 16:29:52
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market I
Filing Documents
- tndm-20251226.htm (8-K) — 32KB
- exhibit31amendedandrestate.htm (EX-3.1) — 165KB
- 0001438133-25-000237.txt ( ) — 348KB
- tndm-20251226.xsd (EX-101.SCH) — 2KB
- tndm-20251226_lab.xml (EX-101.LAB) — 22KB
- tndm-20251226_pre.xml (EX-101.PRE) — 13KB
- tndm-20251226_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the "Company"), the Company's board of directors (the "Board") adopted Amended and Restated Bylaws of the Company (the "Amended and Restated Bylaws"), which became effective immediately and amended and restated the Company's prior bylaws (the "Prior Bylaws"). The Amended and Restated Bylaws reflect the following principal changes from the Prior Bylaws: Advance Notice Provisions. The amendments update the advance notice provisions that apply when a stockholder intends to propose a director nomination or other business at a stockholder meetingby, among other things: requiring any stockholder submitting a nomination notice to make a representation as to whether such stockholder intends to solicit proxies in support of its director nominee(s) in accordance with Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended ("Rule 14a-19"), and to provide reasonable evidence that certain requirements of such rule have been satisfied; providing that the nomination of each proposed stockholder-nominated director nominee be disregarded (notwithstanding that the nominee is included as a nominee in the Company's proxy statement, notice of meeting or other proxy materials for any stockholder meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect of the election of such proposed nominees may have been received by the Company) if, after a stockholder provides notice pursuant to Rule 14a-19, such stockholder subsequently fails to comply with the requirements of Rule 14a-19, fails to timely provide reasonable evidence to the Company that certain requirements of such rule have been satisfied or fails (directly or through a qualified representative) to appear at the stockholder meeting to present the nomination; provi
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Number Description 3.1 Amended and Restated Bylaws of Tandem Diabetes Care, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tandem Diabetes Care, Inc. By: /s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary Date: December 30, 2025 4